Expanding the clinical trial portfolio for lung cancer
Subgroup analysis of OAK trial data supports use of atezolizumab in patients with NSCLC
Blood samples for detecting actionable oncogenic mutations in lung cancer
News from ASCO 2016 for melanoma
Is pembrolizumab alone sufficient to treat bladder cancer?